Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 728 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Schedule B Clear all
Terminated Phase 2 Interventional Results available

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

NCT00609622
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
sunitinib, mFOLFOX6, bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
81
States / cities
Fairhope, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

NCT00628628
View directory record Official record
Conditions
Tumor Lysis Syndrome
Interventions
As Needed Rasburicase, Fixed Dose Rasburicase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Exercise-based Motivational Interviewing for Fibromyalgia

NCT00573612
View directory record Official record
Conditions
Fibromyalgia
Interventions
Attention Control Counseling, Motivational Interviewing
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Kind Minds Program for Youth With Anxiety and Depression

NCT05353751
View directory record Official record
Conditions
Child Anxiety, Depression
Interventions
Kind Minds Program
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Imperial, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit

NCT02957565
View directory record Official record
Conditions
Malignant Neoplasms of Independent (Primary) Multiple Sites, Advanced Cancer
Interventions
Baseline Questionnaires, Videos, Assessment Questionnaires
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Not applicable Interventional

Hyperfractionated Dual Equivalent Fractionated Radiation Therapy

NCT06898905
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Bridging Radiation Therapy
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

PREHEVBRIO Pregnancy Outcomes Registry

NCT06097312
View directory record Official record
Conditions
Vaccine Exposure During Pregnancy
Interventions
Data collection
Other
Lead sponsor
VBI Vaccines Inc.
Industry
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2032
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Not applicable Interventional

Connect2Care: Prostate Cancer Education and Screenings for African American Men

NCT07055165
View directory record Official record
Conditions
Prostate Cancer, Health Behavior
Interventions
Prostate Cancer Genius App, US Prevention Taskforce App
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
45 Years to 69 Years · Male only
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma

NCT00695786
View directory record Official record
Conditions
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage III Small Lymphocytic Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Ann Arbor Stage IV Small Lymphocytic Lymphoma
Interventions
Lenalidomide, Rituximab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Phase 2 Interventional

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

NCT07837973
View directory record Official record
Conditions
Overweight , Obesity, Adults
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Withdrawn Phase 1 Interventional

Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)

NCT02313844
View directory record Official record
Conditions
BK Virus Infection
Interventions
Viralym-B
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

NCT07193511
View directory record Official record
Conditions
Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer
Interventions
AVZO-103, Combination Agent
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

NCT02915744
View directory record Official record
Conditions
Metastasis, Breast Cancer
Interventions
NKTR-102, Eribulin, Ixabepilone, Vinorelbine, Gemcitabine, Paclitaxel, Docetaxel, Nab-paclitaxel
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Tucson, Arizona • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

NCT00001131
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin, HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Early Phase 1 Interventional Results available

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

NCT02913430
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fulvestrant, Tamoxifen, Palbociclib
Drug
Lead sponsor
Shannon Puhalla
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Phase 1 Interventional

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

NCT07216105
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
FT836, Cetuximab, Trastuzumab
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Active, not recruiting Not applicable Interventional

A Study Of Virtual Reality Vs Sham VR On Fibromyalgia

NCT07202572
View directory record Official record
Conditions
Fibromyalgia
Interventions
TRIPP VR Meditation, Sham VR
Device · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 1 Interventional

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT04540796
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
JNJ-75348780
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT01348919
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CEP-18770, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Augusta, Georgia • Lexington, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 20, 2026, 4:51 PM EDT
Terminated Phase 1 Interventional

Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation

NCT01610999
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Lymphoma, Multiple Myeloma
Interventions
Plerixafor
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Resurgence as Choice: Basic and Clinical Studies

NCT03423940
View directory record Official record
Conditions
Problem Behavior, Self-injury, Communication
Interventions
Functional communication training
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
3 Years to 19 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Not applicable Interventional

Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication

NCT05509998
View directory record Official record
Conditions
First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
Interventions
Screening Method (SM), Screening and Communication Method (SCM)
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 30 Years
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Not applicable Interventional

3D Ultrasound Breast Imaging

NCT04692818
View directory record Official record
Conditions
Breast Tumor
Interventions
GE Logiq E10 clinical ultrasound scanner, Verasonics research scanner
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 1 Interventional

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

NCT00732420
View directory record Official record
Conditions
Solid Tumours
Interventions
topotecan, pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 20, 2026, 4:51 PM EDT